SCHEMBL7205197

SCHEMBL7205197

C=CCOC(=O)CC(N)CCC(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.46
CYP2D6 P10635 2/20 0.46
NFKB1 P19838 2/20 0.46
SLC6A2 P23975 1/20 0.46
SLC6A4 P31645 1/20 0.46
BLM P54132 1/20 0.46
SLC6A3 Q01959 1/20 0.46
MEN1 O00255 1/20 0.46
CYP2C19 P33261 1/20 0.46
KMT2A Q03164 1/20 0.46
ENPEP Q07075 5/20 0.43
ANPEP P15144 3/20 0.43
TDP1 Q9NUW8 1/20 0.41
GABRP O00591 2/20 0.37
GABRD O14764 2/20 0.37
GABRA1 P14867 2/20 0.37
GABRB1 P18505 2/20 0.37
GABRG2 P18507 2/20 0.37
GABRB3 P28472 2/20 0.37
GABRA5 P31644 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11298080 0.84 TDP1 (0.40) TSHRCYP2D6NFKB1SLC6A2SLC6A4
SCHEMBL2518196 0.77 CYP2D6 (0.50) TSHRCYP2D6NFKB1SLC6A2SLC6A4
SCHEMBL176230 0.77 CYP2D6 (0.50) TSHRCYP2D6NFKB1SLC6A2SLC6A4
SCHEMBL8972056 0.76 TSHR (0.53) TSHRSLC6A2SLC6A4BLMSLC6A3
SCHEMBL18921054 0.76 TSHR (0.53) TSHRSLC6A2SLC6A4BLMSLC6A3
SCHEMBL2201794 0.75 GRIK1 (0.47) TSHRTDP1GRIK1GRIA1GRIA2
SCHEMBL2201786 0.75 GRIK1 (0.47) TSHRTDP1GRIK1GRIA1GRIA2
SCHEMBL1547587 0.75 TSHR (0.53) TSHRCYP2D6NFKB1SLC6A2SLC6A4
SCHEMBL90430 0.74 TSHR (0.55) TSHRCYP2D6NFKB1SLC6A2SLC6A4
Hydrochloric Acid SCHEMBL29425835 0.74 GRIK1 (0.46) TSHRTDP1GRIK1GRIA1GRIA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6605723-B2 Reacting a protected amino acid ester with a 4-substituted butyric acid derivative, cyclizing the protected intermediate, benzylating and decarboxylating the intermediate, asymmetric hydrogenation using a catalyst HOFFMAN-LA ROCHE INC. 2003-08-12 US disclosed
US-20010037026-A1 Process for the preparation of ethanesul fonyl-piperidine derivatives EVOTEC INTERNATIONAL GMBH (DE) 2001-11-01 US disclosed
EP-1136475-A1 Piperidine and piperazine compounds for use in the treatment of Alzheimer F. HOFFMANN-LA ROCHE AG (CH) 2001-09-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010037026-A1 Process for the preparation of ethanesul fonyl-piperidine derivatives GRIN1, GRIN3A, GRIN2B TSHR 1354/4885CYP2D6 662/4885NFKB1 467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.